Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study
Current Oncology · 2025
DOI: 10.3390/curroncol32110639 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Current Oncology, 2025. Verfasst von İlknur Deliktaş Onur und 29 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Abdurrahman Yurtaslan, Department of Medical Oncology, Ankara Oncology Education and Research Hospital, University of Health Sciences, 06200 Anka…. Hauptthemen laut MEDLINE: Microsatellite Instability, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal tumors constitute 5% of metastatic colorectal cancer(mCRC). Immunotherapy is a new standard, but it is difficult to provide for all patients. 5-Flurouracil-based treatment with anti-EGFRs (cetuximab and panitumumab) in RAS/BRAF-wild or anti-VEGF (bevacizumab) is used in mCRC. Data is limited for the efficacy of anti-VEGF or anti-EGFRs in dMMR/MSI-H mCRC due to the small number of cases in the colorectal cancer population in trials.
Aims
To evaluate prognostic factors in dMMR/MSI-H mCRC and compare progression-free survival time of patients receiving anti-VEGF and anti-EGFR combined with first-line 5FU-based therapy.
Methods
Patients with metastatic dMMR/MSI-H colorectal cancer diagnosed between January 2015 and January 2023 were included in this cohort study. Progression-free survival times of patients treated with first-line therapy were compared. Prognostic factors associated with overall survival were investigated.
Results
A total of 132 patients were included. Mutation rates were 35.6% (n:47) for RAS and 12.1% (n: 16) for BRAF (. Median progression-free survival (PFS) was 10.9 (95% CI: 9.2–12.6) months. Median overall survival (OS) was 44 months (95% CI: 26.23–63.03). 82 (62.1%) patients had primary tumor resection (PTR), 26 (19.7%) had PTR and metastasectomy. A total of 17 (12.8%) de novo mCRC patients had maximal cytoreductive surgery (MCS). A total of 14 (10.6%) patients had subsequent immunotherapy (IO). In multivariate analysis, RAS/BRAF mutation status, MCS, and subsequent IO are defined as prognostic factors for OS (p < 0.01, p: 0.022, and p: 0.005, respectively). No statistically significant difference (PFS, OS) was found in patients receiving first-line anti-VEGF or anti-EGFR therapy. Conclusions: dMMR/MSI-H mCRC is an entity with different tumor biology. We consider that dMMR/MSI-H mCRC patients with BRAF wild, MCS and subsequent IO have better outcomes with 1st line 5FU-based treatment with anti-VEGF/anti-EGFRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Abdurrahman Yurtaslan, Department of Medical Oncology, Ankara Oncology Education and Research Hospital, University of Health Sciences, 06200 Ankara, Turkey.
- Department of Medical Oncology, Memorial Şişli Hospital, 34384 İstanbul, Turkey.
- Department of Medical Oncology, University of Hacettepe, 06800 Ankara, Turkey.
- Department of Medical Oncology, Bilkent City Hospital, University of Health Sciences, 06200 Ankara, Turkey.
- Department of Medical Oncology, University of Dokuz Eylül, 35210 İzmir, Turkey.
- Department of Medical Oncology, University of Necmettin Erbakan, 42310 Konya, Turkey.
ORCID-Profile: İlknur Deliktaş Onur, Taha Koray Sahin, Eda Karapelit, Nargiz Majidova, Elif Şahin, Sabin Göktaş, Ali Oğul, Emine Türkmen, Zeynep Yüksel Yaşar, Yakup Ergün, Sinem Akbaş, Ömer Dizdar, Tuğba Başoğlu, Öztürk Ateş
Zitieren
APA
Deliktaş Onur, İ., Doğan, M., Öztürk, M. A., Sahin, T. K., Kiracı, M., Arslan, A. M., Karapelit, E., Karaoğlan, B. B., Majidova, N., Şahin, E., Göktaş, S., Sakin, A., Oğul, A., Türkmen, E., Başkurt, K., Yüksel Yaşar, Z., Ergün, Y., Türkmen Bekmez, E., Yıldırım Dişli, Ş., …, & Ateş, Ö. (2025). Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study. Current Oncology. https://doi.org/10.3390/curroncol32110639
Vancouver
Deliktaş Onur İ, Doğan M, Öztürk MA, Sahin TK, Kiracı M, Arslan AM, et al. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study. Current Oncology. 2025. doi:10.3390/curroncol32110639
BibTeX
@article{DeliktaOnur2025,
author = {Deliktaş Onur, İlknur and Doğan, Mutlu and Öztürk, Mehmet Akif and Sahin, Taha Koray and Kiracı, Murat and Arslan, Ahmet Melih and Karapelit, Eda and Karaoğlan, Bahar Beliz and Majidova, Nargiz and Şahin, Elif and Göktaş, Sabin and Sakin, Abdullah and Oğul, Ali and Türkmen, Emine and Başkurt, Kadriye and Yüksel Yaşar, Zeynep and Ergün, Yakup and Türkmen Bekmez, Esma and Yıldırım Dişli, Şafak and Akbaş, Sinem and Türker, Sema and Dizdar, Ömer and Bal, Öznur and Yavuzşen, Tuğba and Karakurt, Melek and Yaşar, Arzu Hatime and Başoğlu, Tuğba and Dane, Faysal and Yalçın, Şuayip and Ateş, Öztürk},
title = {Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32110639}
}
EUVIMED